Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Dyspnea in Patients With Pulmonary Fibrosis
This study is currently recruiting participants.
Verified by University of California, San Francisco, January 2008
Sponsors and Collaborators: University of California, San Francisco
University of Chicago
American College of Chest Physicians
The John A. Hartford Foundation
Association of Specialty Physicians, Inc.
Information provided by: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT00611182
  Purpose

This study has two aims:

  1. To determine the relationship of shortness of breath (dyspnea) to other conditions present in patients with pulmonary fibrosis.
  2. To define the relationship between shortness of breath and rate of functional decline in patients with pulmonary fibrosis.

Condition
Pulmonary Fibrosis

MedlinePlus related topics: Breathing Problems Pulmonary Fibrosis
U.S. FDA Resources
Study Type: Observational
Study Design: Cohort, Prospective
Official Title: Dyspnea in Patients With Pulmonary Fibrosis

Further study details as provided by University of California, San Francisco:

Primary Outcome Measures:
  • Dyspnea [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Functional status [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Biospecimen Retention:   None Retained

Biospecimen Description:

Estimated Enrollment: 70
Study Start Date: January 2008
Estimated Study Completion Date: January 2010
Estimated Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Patients with Pulmonary Fibrosis

Detailed Description:

Idiopathic Pulmonary Fibrosis is the most common form of chronic fibrosing lung disease seen by pulmonologists, with an estimated 128,000 cases in the United States alone. It is almost surely a disorder related to aging, with a median age at the time of diagnosis of approximately 65 years; IPF is almost unheard of under the age of 50. Dyspnea is common in patients with IPF, and is often the primary symptom of the disease. It is tightly linked to quality of life in IPF, suggesting that the experience of dyspnea has wide-ranging and clinically-significant consequences. Despite its importance, surprisingly little is known about the etiology or functional impact of dyspnea in this disease.

This research proposal focuses on defining the relationship of dyspnea to comorbidity and the rate of functional decline in patients with IPF

Aim 1: To determine the relationship of dyspnea to other conditions present in patients with IPF.

Dyspnea is a complex symptom, related to both mechanical and cognitive factors. The mechanisms of dyspnea in IPF remain unknown, but there are several likely contributors that are both IPF and non-IPF related. Although IPF is a chronic disease of the elderly, no one has investigated the relationship between common geriatric conditions and dyspnea. It is well established that the perception of dyspnea depends equally on factors that influence the intensity of the experience of breathlessness (such as thoracic restriction and weakness) and the distress which that intensity produces. Gender, ethnicity, anxiety, pain, and depression all may contribute to the distress caused by dyspnea (and therefore its intensity) in IPF.

Aim 2: To define the relationship between dyspnea and rate of functional decline in IPF.

Numerous studies have looked at predictors of survival in patients with IPF, and both baseline and change in dyspnea over time have been shown to be significantly associated. The prediction of future morbidity, however, is largely unstudied. Established markers of functional decline in geriatric patients include weight loss, decline in walking speed over 4 meters, and the onset of disability as defined by the ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs). Dyspnea likely impacts patients' activity levels and/or motivation to stay active, and may contribute to worsening functional decline.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

community sample

Criteria

Inclusion Criteria:

  • 18 years of age and older with pulmonary fibrosis, and able to travel to University of California San Francisco for study visits

Exclusion Criteria:

  • None
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00611182

Contacts
Contact: Harold R Collard, MD 415-353-1043 hal.collard@ucsf.edu
Contact: Jane Berkeley, BA 415-353-1071 jane.berkeley@ucsf.edu

Locations
United States, California
University of California San Francisco Recruiting
San Francisco, California, United States, 94143
Principal Investigator: Harold R. Collard, MD            
Sponsors and Collaborators
University of California, San Francisco
University of Chicago
American College of Chest Physicians
The John A. Hartford Foundation
Association of Specialty Physicians, Inc.
Investigators
Principal Investigator: Harold R. Collard, MD University of California, San Francisco
  More Information

UCSF Interstitial Lung Disease Program  This link exits the ClinicalTrials.gov site

Responsible Party: University of California San Francisco ( Harold R. Collard, MD; Assistant Clinical Professor of Medicine )
Study ID Numbers: H5476-31357-01
Study First Received: January 28, 2008
Last Updated: November 24, 2008
ClinicalTrials.gov Identifier: NCT00611182  
Health Authority: United States: Institutional Review Board

Keywords provided by University of California, San Francisco:
dyspnea
pulmonary fibrosis
interstitial lung disease
shortness of breath

Study placed in the following topic categories:
Lung Diseases, Interstitial
Respiratory Tract Diseases
Fibrosis
Lung Diseases
Dyspnea
Pulmonary Fibrosis

Additional relevant MeSH terms:
Pathologic Processes

ClinicalTrials.gov processed this record on January 15, 2009